[india-drug] Response to WHO statement on removal of two AIDS

["Dr. Usha Gupta" <usha_gupta2@yahoo.com>]

medicines
Sender: owner-india-drug@usa.healthnet.org
Precedence: bulk
Reply-To: india-drug@usa.healthnet.org

Dear I - Drug Participants,
It is a matter of great concern that bioequivalance studies of 
antiretroviral drugs carried out in some centers in India have been
questioned. 
All those who are engaged in conducting such studies must ensure that 
the credibility of their work is maintained. Even pharmaceutical 
industry must ensure that they select the centers who are following GCP
and 
GLP. Such a situation, I feel, has given a blow to industry as well as 
research scientists of this country.


Dr Usha Gupta


________________________________________________________________________
Yahoo! India Careers: Over 50,000 jobs online
Go to: http://yahoo.naukri.com/

Access Essential Drugs Monitor #32 at http://www.who.int/medicines/mon/mon32.shtml

The INDIA-DRUG discussion group is a partnership between SATELLIFE
(www.healthnet.org), WHO Essential Drugs and Medicines Policy
(www.who.ch), and the Delhi Society for the Promotion of the
Rational Use of Drugs (DSPRUD) in India.

To send a message to india-drug, write to: india-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe india-drug OR unsubscribe india-drug
To contact a person, send a message to: india-drug-help@healthnet.org